A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
CD8
GEJ
PD-L1
adenocarcinoma
esophageal gastric
immune checkpoint inhibitor (ICI)
pathological response (ypRR)
pembrolizumab
perioperative
tumor regression score (TRS)
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
25
05
2023
received:
22
02
2023
accepted:
06
06
2023
medline:
1
9
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Perioperative chemotherapy/chemoradiation is standard in esophageal/gastric/gastroesophageal junction (GEJ) adenocarcinoma, immune checkpoint inhibitors (ICI) effect in setting of metastatic and postoperatively. This study is to assess ICI + chemotherapy perioperatively. Patients with locally advanced (T1N1-3M0 or T2-3NanyM0) potentially resectable esophageal/gastric/GEJ adenocarcinoma by PET/EUS/CT and staging-laparoscopy, were treated preoperative 4 cycles mFOLFOX6 (Oxaliplatin 85 mg/m Thirty-seven patients completed the preoperative treatment. Twenty-nine patients had curative R0 resection. 6/29 (21%; 95% CI: 0.08-0.40) achieved ypCR with TRS 0 in resected patients. 26/29 (90%; 95% CI: 0.73-0.98) had ypRR with TRS ≤2. Twenty-six patients finished adjuvant therapy with a median 36.3-month follow-up. Three patients had recurrence/metastatic disease (at 9-, 10-, 22 months enrollment) with one dead at 23 months, and two are still alive at 28 and 36.5 months. The remaining (23/26) are free of disease with 3 years DFS of 88.5% and 3 years OS of 92.3%. There were no unexpected toxicities. Preoperative ICI + chemotherapy enhanced immune responses significantly with increasing expression of PD-L1 (CPS ≥10, p = 0.0078) and CD8 (>5%, p = 0.0059). The perioperative pembrolizumab and mFOLFOX combination in resectable esophageal/gastric/GEJ adenocarcinoma is very effective with 90% ypRR, 21% ypCR, and impressive long-time survival benefits.
Sections du résumé
BACKGROUND
Perioperative chemotherapy/chemoradiation is standard in esophageal/gastric/gastroesophageal junction (GEJ) adenocarcinoma, immune checkpoint inhibitors (ICI) effect in setting of metastatic and postoperatively. This study is to assess ICI + chemotherapy perioperatively.
METHODS
Patients with locally advanced (T1N1-3M0 or T2-3NanyM0) potentially resectable esophageal/gastric/GEJ adenocarcinoma by PET/EUS/CT and staging-laparoscopy, were treated preoperative 4 cycles mFOLFOX6 (Oxaliplatin 85 mg/m
RESULTS
Thirty-seven patients completed the preoperative treatment. Twenty-nine patients had curative R0 resection. 6/29 (21%; 95% CI: 0.08-0.40) achieved ypCR with TRS 0 in resected patients. 26/29 (90%; 95% CI: 0.73-0.98) had ypRR with TRS ≤2. Twenty-six patients finished adjuvant therapy with a median 36.3-month follow-up. Three patients had recurrence/metastatic disease (at 9-, 10-, 22 months enrollment) with one dead at 23 months, and two are still alive at 28 and 36.5 months. The remaining (23/26) are free of disease with 3 years DFS of 88.5% and 3 years OS of 92.3%. There were no unexpected toxicities. Preoperative ICI + chemotherapy enhanced immune responses significantly with increasing expression of PD-L1 (CPS ≥10, p = 0.0078) and CD8 (>5%, p = 0.0059).
CONCLUSIONS
The perioperative pembrolizumab and mFOLFOX combination in resectable esophageal/gastric/GEJ adenocarcinoma is very effective with 90% ypRR, 21% ypCR, and impressive long-time survival benefits.
Identifiants
pubmed: 37326317
doi: 10.1002/cam4.6263
pmc: PMC10469814
doi:
Substances chimiques
pembrolizumab
DPT0O3T46P
B7-H1 Antigen
0
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16098-16107Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM130423
Pays : United States
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Med. 2023 Aug;12(15):16098-16107
pubmed: 37326317
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer. 2017 Nov 1;123(21):4106-4113
pubmed: 28885712
J Clin Oncol. 2021 Jun 20;39(18):1995-2004
pubmed: 33891478
Anticancer Res. 2022 Jan;42(1):195-203
pubmed: 34969725
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35649657
Lancet. 2012 Jan 28;379(9813):315-21
pubmed: 22226517
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
Lancet. 2021 Aug 28;398(10302):759-771
pubmed: 34454674
Anticancer Res. 2022 Jan;42(1):185-193
pubmed: 34969724
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137